第 3 页 · 按发布时间倒序聚合。
TechnipFMC is a focused subsea production-systems and SURF contractor whose earnings are anchored by a record offshore order book. A 16.57 billion USD backlog, free cash flow that doubled to 1.45 billion USD, and a swing to net cash have re-rated it from a post-merger cleanup story into a cyclical-quality franchise. Rating Hold: a genuinely better subsea business, but at 64.44 USD the price already discounts most of the backlog and cash-conversion improvement, leaving a thin margin of safety.
UCB is a Belgian specialty biopharma in immunology and neurology, and BIMZELX is now its largest product at €2.227 billion of 2025 net sales. FY2025 revenue rose 26% to €7.741 billion, adjusted EBITDA jumped to €2.636 billion, and the balance sheet swung from €1.454 billion of net debt to roughly net cash; yet at €258.50, about 24x forward earnings, the price already embeds much of the BIMZELX and portfolio ramp. Rating Hold: a genuinely stronger company at a price that leaves essentially no margin of safety for fresh capital.
Hecla Mining is North America's largest silver producer, now a debt-free, three-mine platform (Greens Creek, Lucky Friday, Keno Hill) that turned the 2025 cyclical upswing into 1.423 billion USD of sales and 310.2 million USD of free cash flow. Asset quality and the balance sheet have genuinely improved, but at 15.54 USD the stock already discounts most of that, and the upside is driven by silver-price beta rather than durable compounding. Rating Hold: a cleaner, better-run silver major worth holding, with no margin of safety for new money until it falls toward the 10-11 USD ideal-buy zone.
Sanofi is a French pure-play biopharma built around immunology, vaccines, and rare disease after ceding control of Opella. Dupixent alone reached 15.714 billion EUR of 2025 sales, about 36% of group revenue, and still grew 30.8% in Q1 2026, yet the market withholds a growth multiple until a post-Dupixent bridge is proven ahead of the roughly 2031 patent cliff. Rating Hold: a cleaner, cash-generative business at a cheapish multiple with 8.089 billion EUR of 2025 free cash flow, but no wide margin of safety on the hard part of the story.
BioMarin is a profitable rare-disease biopharma whose enzyme franchise generated about 2.106 billion USD of 2025 revenue and funds the company, while VOXZOGO (926.9 million USD) drives both growth and sentiment. The Amicus acquisition diversified the portfolio into Fabry and Pompe disease and lifted 2026 revenue guidance to 3.825-3.925 billion USD, yet weekly and oral achondroplasia rivals from Ascendis and BridgeBio keep the margin of safety thin. Rating Hold: cash generation and Amicus diversification make BioMarin sturdier than sentiment implies, but VOXZOGO competition caps the upside at today's price.
Panasonic Holdings is a diversified Japanese electronics group whose earnings base is still mature B2B and appliance operations, while batteries and AI-infrastructure products drive the growth narrative. FY2026 sales were ¥8.05 trillion across six segments, but ROE fell to 3.8% on ¥174.5 billion of restructuring charges, and the shares are up about 68% in 2026 on an AI-infrastructure rerating that capitalizes one hot battery-and-data-center engine across the whole group. Rating Hold: the business mix is genuinely improving, but at ¥4,540 the price already discounts most of the battery, AI-infrastructure, and restructuring upside, leaving no margin of safety against a conservative fair value near ¥2,400-¥2,690.
Symrise is a scaled, oligopolistic flavors-and-fragrances and nutrition platform that gets paid for being embedded in customers' everyday products, with 2025 sales of €4.93 billion, a 21.9% adjusted EBITDA margin and record €780 million of business free cash flow. The 2026 question is delivery, not discovery: organic growth has cooled from 8.7% in 2024 to low single digits in 2025 and slightly negative in Q1 2026, yet cash conversion, leverage and margin quality all improved, so the franchise is intact while the near-term growth premium is not obviously earned. Rating Hold: a high-quality compounder whose €88.16 price already reflects most of the self-help and recovery, with a more comfortable margin of safety only in the high-€50s to mid-€60s.
JD.com is China's largest self-operated online retailer, built on a supply-chain-first model spanning first-party retail, marketplace services, logistics, health and industrial procurement. Its retail core is strengthening, with JD Retail operating margin up to 5.6% in Q1 2026 and net service revenue growing 20.6% against just 1.0% product growth, yet group profit and cash conversion are obscured by heavy food-delivery and overseas investment, while listed-subsidiary stakes worth about US$17.7 billion anchor a sum-of-the-parts case. Rating Cautious Buy: the market discounts the cost of transition more than it credits a stronger retail core, large buybacks and visible listed stakes.
FUJIFILM Holdings is a diversified Japanese technology group earning ¥3.36 trillion of FY2026 revenue across healthcare and Bio CDMO, semiconductor materials, imaging (instax) and office systems. Electronics and Imaging already supply about ¥260.9 billion, roughly three-quarters of segment operating profit, yet Healthcare ROIC is only 1.6%, FY2026 free cash flow is negative amid a capex bulge, and owner earnings near 23 times sit well above the 15.7 times headline P/E. Rating Hold: the transformation from film survivor to multi-engine compounder is real, but healthcare returns and owner earnings still lag the price, leaving no margin of safety until below ¥2,650.
ACM Research is a Nasdaq-listed holding company whose value is dominated by its roughly 73.6%-owned, Shanghai-listed subsidiary ACM Shanghai, built on a single-wafer wet-cleaning franchise now broadening into plating, furnace, track and PECVD. The parent trades at a steep discount to the quoted value of that stake, yet the A-share quote is already rich, four customers make up 52.2% of 2025 revenue, and first-quarter 2026 free cash flow was negative 52.1 million USD. Rating Hold: strong China semicap execution is real, but at 104.50 USD the price offers too little protection against cash-conversion, policy and holdco-structure risk.
Bentley Systems is a specialized infrastructure-engineering software vendor whose economic engine is a recurring estate embedded in civil, utility, and owner-operator workflows, with $1.495 billion ARR, 93% recurring revenue, 99% account retention, and 109% net retention. Full-year 2025 revenue rose 11.0% to $1.502 billion and free cash flow reached $520.2 million, yet a dual-class structure leaves the Bentley Control Group with about 62.8% of voting power and the $30 price sits roughly at conservative fair value. Rating Hold: a high-quality, sticky compounder whose cash conversion the headline P/E understates, but founder control and a thin margin of safety make a fresh buy more attractive below $25.
Black Sesame is a fabless designer of automotive compute SoCs, selling ADAS chips and bundled solutions; 2025 revenue rose 73% to RMB822 million, yet it stays deeply loss-making with R&D near 1.7x sales. It has crossed the technical-credibility threshold (A1000 shipping in Geely, BYD and FAW models) but not the cash-conversion one, leaning on repeated 2025-2026 equity raises. Rating Hold: real commercialization exists, but recurring dilution and negative owner earnings cap valuation support, with a true margin of safety only below about HK$6.
Belimo is the Swiss pure-play leader in HVAC field devices (the actuators, control valves, sensors and meters that regulate heating, cooling and ventilation), selling through contracting and retrofit channels at about 60% of sales and OEM channels at about 40% without competing with the integrated building-automation giants it supplies. In 2025 sales rose 23.3% in local currencies to CHF 1,120.8 million with a 20.8% EBIT margin and 27.8% ROIC, as AI data-center liquid cooling at about 17% of sales became a second growth engine on top of a durable energy-efficiency retrofit franchise, yet at roughly 61x trailing earnings the stock sits near the top of its own historical range. Rating Watch: a genuinely excellent niche compounder whose price already discounts excellence plus a long AI-cooling runway, with a more attractive entry only below roughly CHF 480.
Sika is the global leader in construction chemicals (admixtures, waterproofing, sealants, roofing and industrial adhesives), selling locally adapted systems through more than 400 factories in over 100 countries, with bolt-on M&A such as Parex and MBCC built into its model. 2025 sales fell 4.8% to CHF 11.20bn on a strong Swiss franc and a soft construction cycle, yet local-currency growth stayed positive and material margin rose to 54.9% while MBCC synergies reached CHF 182m. Rating Hold: a first-rate serial-acquirer compounder caught in a cyclical air pocket, but at roughly 26x trailing earnings the valuation already prices much of the margin recovery before organic growth has returned.
NARI is the dominant listed proxy for China's grid-control layer: dispatch software, relay protection, UHV control and energy-management systems built around State Grid. 2025 revenue reached RMB 66.23bn with operating cash flow of RMB 12.77bn, yet revenue is outgrowing profit as the mix shifts toward lower-margin storage and outside-grid work. Rating Hold: a high-quality policy-cycle compounder whose roughly 22x trailing valuation leaves little margin of safety against further mix dilution.
AVIC Jonhon is a Chinese high-reliability interconnect maker whose defense-grade connector core still carries the business (connectors are 98.5% of revenue) while EVs, data centers and optics become the larger growth engine. 2025 revenue edged up 3.4% to RMB 21.39 billion but attributable profit fell 35.6% to about RMB 2.16 billion as defense demand softened and gold, copper and silver costs surged, and at RMB 42.69 the stock already trades on a mid-40s trailing multiple that discounts a recovery while cash conversion stays weak. Rating Hold: the franchise is intact and a rebound is plausible, but today's price pre-spends most of it with no margin of safety.
Straumann is the global leader in specialty dentistry, a Swiss platform that grew from a premium implant maker into a multi-brand, multi-price-point group spanning implants, digital workflows, biomaterials, prosthetics, and clear aligners, with CHF 2.61 billion of 2025 revenue and about 35% of a CHF 6.0 billion implant market. The franchise quality is genuine (ROCE 30.6%, equity ratio 57.6%, a decade of share gains), but gross margin has drifted from 76.2% to 68.6% and free-cash-flow margin from 21.8% to 11.1% as value-tier and digital mix grew, and the stock trades near 35.8x core earnings on a 1.7% free-cash-flow yield. Rating Hold: a high-quality compounder with a long runway, but the price already discounts much of the next margin and ecosystem leg, leaving little margin of safety.
GSK plc is a UK biopharma rebuilt around vaccines and specialty medicines after the 2022 Haleon demerger, with 2025 sales of £32.7bn anchored by Shingrix and the ViiV HIV franchise. Specialty medicines now drive growth (£13.5bn, +14% CER in Q1 2026) and core operating profit rose 11% to £9.8bn, yet the whole story hinges on replacing the dolutegravir HIV cliff in 2028–2030 before it arrives. Rating Hold: a genuinely higher-quality franchise at roughly 11.6x core earnings, but the price already assumes much of the patent-cliff bridge, leaving little margin of safety.
Sungrow Power Supply is a founder-led global leader in solar inverters and energy-storage systems, with overseas sales at 60.7% of 2025 revenue and storage now its largest segment at 41.9% of sales. Operating cash flow climbed to CN¥16.9 billion and receivables improved, yet Q1 2026 revenue fell 18.3% and profit 40.1%, exposing sharp margin-mix cyclicality beneath the quality story. Rating Hold: a genuine quality-growth franchise trading at a premium that leaves little margin of safety for execution misses.
Major indexes edged lower as an AI and semiconductor reset outweighed better breadth, cheaper oil, and lower Treasury yields.
Games Workshop is the vertically integrated owner of the Warhammer universe, designing, manufacturing and selling miniatures, paints, books and licensed media from a single UK creative stack at returns on capital few public companies reach. FY2025 delivered £617.5m of total revenue and £262.8m of profit before tax, and FY2026 is guided higher even as the volatile licensing line steps down from £52.5m to at least £30m. Rating Hold: an exceptional IP compounder whose roughly 35x earnings multiple already prepays years of flawless execution, leaving no margin of safety at £217.
Simulations Plus builds scientifically trusted drug-development modeling software (GastroPlus, MonolixSuite, ADMET Predictor, DILIsym), but its revenue mix has drifted toward lower-margin services since the 2024 Pro-ficiency acquisition, which pulled FY2025 gross margin to 58% and triggered a $77.2m impairment. On 2026-06-26 the equity trades as a near-cash event security: Altaris' agreed $18.50-per-share takeout caps upside just above the $18.14 close, while a broken deal would reopen real downside. Rating Avoid: a thin-spread cash-deal security whose unresolved software-mix question still sits underneath the transaction.
Carl Zeiss Meditec is a premium German ophthalmology and microsurgery franchise where ophthalmology drives about 77% of sales and recurring revenue has climbed from 9% two decades ago to roughly 50%. A simultaneous China VBP shock and weak Americas equipment demand crushed H1 FY2025/26 adjusted EBITA margin to 6.1% from 10.7%, and the shares have fallen more than 80% from their 2021 peak to 27.96 euros. Rating Watch: a high-quality medtech franchise in a real trough, but the China relisting and margin-restoration bridge is still too unproven for a clean entry, with the ideal buy zone at 24 to 26 euros.
SAP is the incumbent enterprise-applications vendor migrating its captive ERP installed base from license-and-support to cloud subscriptions, where process centrality keeps converting into long-duration economics. In 2025 cloud revenue reached 21.0 billion euros and predictable revenue 86%, with total cloud backlog of 77.3 billion euros, yet FY2026 guidance for slightly decelerating current-backlog growth reset the stock more than 50% below its early-2025 peak to about 21.5x earnings. Rating Hold: the cloud transition is genuinely working and the franchise is high quality, but at today's price the market already asks for proof rather than possibility, with the ideal buy zone at 95 to 101 euros.
Shimano is a century-old Japanese precision manufacturer whose bicycle drivetrain and braking franchise still drives roughly three-quarters of group sales, with fishing tackle the resilient second engine. Group operating income has fallen from a 169.2 billion yen pandemic peak in 2022 to a guided 47.0 billion yen in 2026 (margin near 10% against a historical 20% to 25%), and at 17,340 yen (about 35x guided earnings) the price already discounts much of the eventual repair, leaving no margin of safety. Rating Hold: a fortress-quality franchise in a real but uncertain trough, where the moat is intact yet the entry price is not yet compelling, with the ideal buy zone at 12,000 to 14,000 yen.
Hengrui Pharmaceuticals is China's largest listed innovative-drug platform, still earning mainly from domestic drug sales while its valuation increasingly rests on converting self-funded R&D into commercial franchises and recurring overseas licensing income. 2025 revenue reached RMB 31.63 billion with net profit of RMB 7.71 billion and a fortress balance sheet holding RMB 40.16 billion of cash, yet at RMB 50.04 (about 41x trailing earnings) the price sits above the conservative fair value and leaves no margin of safety. Rating Hold: a rare high-quality China pharma platform already priced for an innovation-monetization upgrade it has not yet fully earned.
U.S. stocks closed mixed in a sector-rotation tape as semiconductor strength offset pressure from mega-cap consumer technology and sticky inflation kept rate risk in focus.
Pan American Silver is an Americas-focused, silver-first precious-metals miner whose September 2025 MAG acquisition added a 44% stake in the high-grade Juanicipio mine, lifting 2026 guidance to 25-27 Moz silver and 700-750 koz gold on a net-cash balance sheet. The portfolio is genuinely better than the 2022 trough, but at $44.39 the stock trades near 9.2x EV/EBITDA on a 7% free-cash-flow yield, already pricing the upgrade while Escobal and Navidad stay politically frozen and 2026 cost guidance leans on $70 silver against roughly $58 spot. Rating Hold: a better silver miner with no clear margin of safety, where a buy needs either the mid-$20s or proof that normalized free cash flow holds closer to the base case than the conservative one.
RemeGen is a commercializing China innovative-biopharma with two self-developed franchises — telitacicept in autoimmune disease and disitamab vedotin in ADC oncology — plus an ex-China licensing engine (Vor Bio, Santen, AbbVie) that has become part of the business model. 2025 product sales reached CNY 2.31bn (up 35.8%) and reported profit turned positive at CNY 709.7m, but operating cash flow was only CNY 52.3m (about 0.07x conversion), Q1 2026 profit after non-recurring items stayed negative, and the A-share trades at roughly a 96.5% premium to the H-share — above even the optimistic per-share value. Rating Avoid: a good company at the wrong price on the Shanghai line, where an entry needs both a lower A-share price (CNY 36-40) and proof that recurring earnings quality has caught up to the approvals.